title: Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience.
abstract: OBJECTIVE
  Preliminary assessment of the efficacy of propranolol on subglottic hemangioma in children on a nation-wide scale.
  
  
  METHODS
  Multicentric, retrospective study of clinical files of 14 children; pre- and post-treatment endoscopies.
  
  
  RESULTS
  Mean age at diagnosis was 2.3 (0.7-4) months. Mean percentage of airway obstruction was 68% (15-90) before propranolol introduction. Propranolol was started at 5.2 (0.7-16) months of age. This treatment was effective in all cases with a mean regression of the stenosis to 22% after 2 weeks and 12% after 4 weeks. Other medical treatments (steroids) could be stopped. In one patient, a side effect of propranolol motivated the switch to another β-blocker. In four patients, treatment was stopped after 5.2 (1-10) months with a relapse in 2 (50%) cases. One of these two patients developed a resistance to propranolol and required a surgical procedure by external approach.
  
  
  CONCLUSIONS
  This preliminary nation-wide survey confirms propranolol high effectiveness against airways' localization of infantile hemangiomas. Propranolol also allows alleviation or cut-off of previous medical treatments. However, recurrences are possible after early treatment interruption.
authors.affiliation: Hôpital Armand-Trousseau, 75012 Paris, France. nicolas.leboulanger@trs.aphp.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Leboulanger
authors.forename: Pierre
authors.initials: P
authors.lastname: Fayoux
authors.forename: Natacha
authors.initials: N
authors.lastname: Teissier
authors.forename: Amanda
authors.initials: A
authors.lastname: Cox
authors.forename: Thierry
authors.initials: T
authors.lastname: Van Den Abbeele
authors.forename: Laure
authors.initials: L
authors.lastname: Carrabin
authors.forename: Vincent
authors.initials: V
authors.lastname: Couloigner
authors.forename: Richard
authors.initials: R
authors.lastname: Nicollas
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Triglia
authors.forename: Sonia
authors.initials: S
authors.lastname: Ayari
authors.forename: Patrick
authors.initials: P
authors.lastname: Froehlich
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Lescanne
authors.forename: Rémy
authors.initials: R
authors.lastname: Marianowski
authors.forename: Thierry
authors.initials: T
authors.lastname: Mom
authors.forename: Michel
authors.initials: M
authors.lastname: Mondain
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Marie
authors.forename: Gilles
authors.initials: G
authors.lastname: Roger
authors.forename: Eréa-Noël
authors.initials: EN
authors.lastname: Garabédian
authors.forename: Françoise
authors.initials: F
authors.lastname: Denoyelle
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000402:Airway Obstruction / Q000188:drug therapy / Q000209:etiology; D004351:Drug Resistance; D006391:Hemangioma / Q000151:congenital / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007822:Laryngeal Neoplasms / Q000151:congenital / Q000188:drug therapy*; D011433:Propranolol / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D014134:Tracheal Neoplasms / Q000151:congenital / Q000188:drug therapy*
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol